Table 7.

Incidence of adverse events (AEs).

Event	PC group	PA group	PAC group	Total	P-value
Blood toxicity	12(33.3%)	6(22.2%)	2 (20%)	20(27.4%)	0.586
Abnormal liver function	2(5.6%)	2(7.4%)	0(0%)	4(5.5%)	1.000
Abnormal renal function	0(0%)	1(3.7%)	0(0%)	1(1.4%)	0.500
Rash	2(5.6%)	1(3.7%)	1(10%)	4(5.5%)	0.628
Hypertension	0(0%)	5(18.5%)	3(30%)	8(11%)	0.003*
Abnormal thyroid function	2(5.6%)	4(14.8%)	3(30%)	9(12.3%)	0.085
Cardiotoxicity	8(22.2%)	2(7.4%)	0(0%)	10(13.7%)	0.146
Pneumonia	1(2.8%)	0(0.0%)	0(0%)	1(1.4%)	1.000

PC group: PD-1/PD-L1 inhibitors plus Chemotherapy.

PA group: PD-1/PD-L1 inhibitors plus anti-angiogenic agents.

PAC group: PD-1/PD-L1 inhibitors plus anti-angiogenic agents plus Chemotherapy.

*PC vs PA P-value=0.011; PC vs PAC P-value=0.008.